아스피린의 항암효과. 전립선암도 예방할 수 있습니다.

100여년 전 버드나무 추출물에서 진통 소염 효과를 가지는
 
아스피린이 발견된 이후 근대 의학의 한 축을 담당해온 소염진통제.
 
요즘은 피를 묽게 만들어 심장병을 예방하고
 
중풍 같은 뇌혈관 질환을​ 억제할 목적으로
 
많이 사용되고 있습니다.​
 
 
이러한 아스피린이 암을 예방하고 이미 발생한 암에 대해서도
 
전이​ 억제 효과가 있다는 논문이 영국의 유명 저널
 
Lancet에 2012년 3월 발표되었는데요,
 
무려 7만 ​7천여명의 대규모 임상연구를 통해서
 
​아스피린 저용량 복용 요법이
 
암에 걸릴 확률을 25% 감소시키고
 
​암으로 인한 사망율도 37% 감소시키는 효과 및
 
암이 이미 걸린 환자에서 전이될 확률을
 
43% 감소시킨다고 밝혔습니다.​
 
 
 
이후로도 대장암 등에 대한 후속 연구들이​
 
많이 시행되었는데요, 비뇨기과의 대표적인 암이라고 할 수 있는​
 
전립선암에 대한 항암효과도 있다고 하니
 
저용량 아스피린 복용 요법을 신중히
 
검토해 보아야 겠습니다.
 
참고 논문:
 
Tumori. 2014 Sep-Oct;100(5):486-90. doi: 10.1700/1660.18156.
Correlation between prolonged use of aspirin and prognostic risk in prostate cancer.
Dell'Atti L.
 
Abstract
Aims and background. In recent years the role of inflammation in cancer etiology has gained attention and several studies have suggested that acetylsalicylic acid and other nonsteroidal anti-inflammatory drugs may have chemopreventive activity and reduce the risk of prostate cancer. We investigated whether there is a correlation between prolonged use of aspirin and prognostic risk in prostate cancer. Methods and study design. From January 2002 to December 2007 we performed 385 radical prostatectomies for localized prostate cancer. Patients were divided into 2 groups: group A (GA) comprised 174 patients who took aspirin 100 mg once daily for 2 years or more; group B (GB) consisted of 211 patients who did not take NSAIDs, or only occasionally. To evaluate the correlation between aspirin use and prognostic risk in prostate cancer we examined the following factors: biochemical recurrence, percentage of positive surgical margins, pathological stage, pathological Gleason score, percentage of positive lymph nodes, and preoperative PSA level. Results. There was no statistical difference in preoperative PSA levels (6.5 and 6.9 ng/mL; P = 0.045) between the 2 groups. The incidence of positive surgical margins was 18.9% in GA and 28.9% in GB (P <0.002). The percentage of positive lymph nodes in patients with positive surgical margins in GB (47.5%) was statistically higher than that in GA (27.2%). With an average follow-up period of 4.6 years, 22.7% of patients in GA and 32.7% in GB developed biochemical recurrence. In the stratified analysis we observed significant differences in the association between prediagnostic aspirin use and prognostic risk for patients with Gleason score 7 and T2 stage of disease. The daily use of aspirin was significantly associated with a lower risk of disease progression, with a hazard ratio of 0.92 (95% CI 0.85-0.99). Conclusions. These results provide further evidence that aspirin may have chemopreventive activity against prostate cancer and highlight the need for additional research. Additional studies with more detailed exposure measurement are warranted to evaluate questions about dose, the best age to begin treatment, and the duration of therapy.